Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
66.52
-1.82 (-2.66%)
At close: Jun 27, 2025, 4:00 PM
66.47
-0.05 (-0.08%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $255.74M in the quarter ending March 31, 2025, with 75.38% growth. This brings the company's revenue in the last twelve months to $803.32M, up 42.93% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$803.32M
Revenue Growth
+42.93%
P/S Ratio
12.61
Revenue / Employee
$334,715
Employees
2,400
Market Cap
11.52B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TEM News
- 2 days ago - Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing - Business Wire
- 3 days ago - Tempus AI Is Well Worth Its Price Tag - Seeking Alpha
- 4 days ago - TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 11 days ago - Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference - Business Wire
- 14 days ago - Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025 - GlobeNewsWire
- 15 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 16 days ago - Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research - Business Wire
- 16 days ago - Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire